Would you use belzutifan in metastatic renal cell carcinoma with somatic mutation in VHL (VHL p.q73) without having germline VHL and/or other manifestations of VHL syndrome?   

Currently, there is no proven role for belzutifan use in somatic VHL mutation RCC. However, phase III clinical trial in advanced pretreated RCC randomizing to everolimus or belzutifan is currently ongoing. Phase II trials conducted in advanced RCC have reported promising results with belzutifan ther...